Federal contract award
75N93019C00060
TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $16.8M |
| Current contract value | $16.8M |
| Potential contract value / ceiling | $22.6M |
| Start date | Sep 4, 2019 |
| Current end date | Apr 24, 2025 |
| Potential end date | Jun 28, 2025 |
| Latest award activity | May 29, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 32 of 32 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 29, 2025 | P00031 | $955.2K | DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIOTHREAT AGENTS, ANTIMICROBIAL-RESISTANT INFECTIONS AND EMERGING INFECTIOUS DISEASES. |
| Apr 24, 2025 | P00030 | $0 | EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIOTHREAT AGENTS, ANTIMICROBIAL-RESISTANT INFECTIONS AND EMERGING INFECTIOUS DISEASES. |
| Dec 19, 2024 | P00029 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Jul 28, 2024 | P00028 | $1.7M | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Jun 12, 2024 | P00027 | $384.1K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| May 28, 2024 | P00026 | $1.1M | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| May 1, 2024 | P00025 | $481.2K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Jan 31, 2024 | P00024 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Dec 4, 2023 | P00023 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Sep 13, 2023 | P00022 | $597.1K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Aug 30, 2023 | P00021 | $2.5M | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Jul 3, 2023 | P00020 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Apr 12, 2023 | P00019 | $700.9K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Mar 7, 2023 | P00018 | $213.7K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Nov 18, 2022 | P00017 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Sep 28, 2022 | P00016 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Aug 22, 2022 | P00015 | $394.2K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Jun 6, 2022 | P00014 | $498.8K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| May 6, 2022 | P00013 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Dec 9, 2021 | P00012 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Oct 25, 2021 | P00011 | $0 | EO14042 - TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Sep 10, 2021 | P00010 | $275.3K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Jun 9, 2021 | P00009 | $441.9K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| May 6, 2021 | P00008 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Apr 26, 2021 | P00007 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Jan 4, 2021 | P00006 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Dec 11, 2020 | P00005 | $676.9K | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Sep 3, 2020 | P00004 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE SAFETY AND LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Apr 9, 2020 | P00003 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE SAFETY AND LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Feb 6, 2020 | P00002 | $3.8M | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE SAFETY AND LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Jan 9, 2020 | P00001 | $0 | TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE SAFETY AND LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS. |
| Sep 4, 2019 | 0 | $2.1M | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.